W. H. Wilson Tang, MD

Opinions are my own.

[Cardiovascular Research Foundation @crfheart]

Three Days. Endless Innovation. 🚀

Dive into pioneering data and transformative innovations in #heartfailure treatment with the program guide: your ultimate resource for navigating #THT2026! https://t.co/BtO3iXZ6ef

Not registered yet? Secure your spot and save when you register before Dec. 17.⌛ https://t.co/0LnGjT2Gut

#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMD @javedbutler1 @preventfailure @akshaydesaimd @JerryEstepMD @FudimMarat @UlrichJordeMD @manreetkanwar @dranulala @MartyBLeon @LindenfeldJoann @SMarxLab @gtsayer @WilsonTangMD @NirUrielMD @jgranadacrf @triciarawh @TCTConference @TCTMD

[W. H. Wilson Tang, MD @WilsonTangMD]

How can we modify the gut microbiome to treat and prevent #HeartFailure? Great talk by @PetraMamicMD at #HFSA2025 @StanfordCVI

[Christopher Nguyen, PhD, FSCMR, FACC @ChrisNguyenPhD]

Annual center picture for @CleClinicCIRC ! We turn 3 years old. We’ve accomplished so much in such a short time. Feel blessed working with the many @CleClinicHVTI Staff, scientists, engineers, and students.

Thanks to the support @LarsSvenssonMD @tavrkapadia @ClevelandClinic

[JACC Journals @JACCJournals]

From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding:
🔸Death/CV 🏥
🔸AF recurrence

Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF

📎: https://t.co/wxPf72B60o #JACCHF

[W. H. Wilson Tang, MD @WilsonTangMD]

Official kickoff of #THT2025 with #heartfailure innovations by @BurkhoffMd @TCTMD @HFSA

[Cardiovascular Research Foundation @crfheart]

🚨 Final Call: Secure Your Discounted Room by January 22!

Stay at the Omni Boston Hotel at the Seaport, the official #THT2025 venue. Rooms are limited — don’t wait!

✅ Registered attendees, use the reservation link in your confirmation email to secure your spot (subject to availability).

Not registered yet? Register now to lock in your stay! https://t.co/H3lbU47uqr

#heartfailure #CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMD @javedbutler1 @preventfailure @akshaydesaimd @JerryEstepMD @FudimMarat @UlrichJordeMD @manreetkanwar @navinkapur4 @dranulala @MartyBLeon @LindenfeldJoann @SMarxLab @gtsayer @WilsonTangMD @NirUrielMD @jgranadacrf @triciarawh @TCTConference

[W. H. Wilson Tang, MD @WilsonTangMD]

@CardioNerdsJC This is in contrast with many HF trials that have resulted in neutral results, in part because many factors (cardiac or extra-cardiac) may affect pVO2 in pts with HF.

[W. H. Wilson Tang, MD @WilsonTangMD]

@CardioNerdsJC This is one scenario that change in pVO2 is a good choice for primary endpoint because the key determinant of pVO2 in oHCM is the obstructive physiology that is being relieved by the intervention.

[W. H. Wilson Tang, MD @WilsonTangMD]

@ChrisKramerMD @CardioNerdsJC Wondering if it is only known LP/P sarc+ vs all got tested.

[AHA Science @AHAScience]

🆕statement on evaluating & managing kidney dysfunction in patients with advanced heart failure.

📷Approach to assessment of kidney dysfunction in advanced HF

✍🏼@nishakidneydoc @WilsonTangMD @RangaswJ @FiedlerAmy @modeldoc @PietermartensMD @JamesCFangMD @CunningBeans @mbakitas

[W. H. Wilson Tang, MD @WilsonTangMD]

@JeroenDauw @WilfriedMullens @FH_Verbrugge @piet_stinissen @pietvandervoort @ECraenenbroeck Congrats!

[Circulation @CircAHA]

#Perspective: Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases @CCLRI @WilsonTangMD https://t.co/oihMAmk7vR

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

Acetazolamide prevents loop diuretic resistance. #THT2024 @WilfriedMullens @WilsonTangMD

[W. H. Wilson Tang, MD @WilsonTangMD]

Great start with our fearless leader @BurkhoffMd kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.

[Eric Topol @EricTopol]

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites
https://t.co/ZZw51MgO0y
@NatureMedicine

[JACC Journals @JACCJournals]

The new #JACCHF issue is now out!

Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. https://t.co/HoRswDCAJe

#CHF @WilsonTangMD

[Christopher Nguyen, PhD, FSCMR, FACC @ChrisNguyenPhD]

So incredibly proud of @ClevelandClinic representation at #CMR2024 in London @SCMRorg. 14 oral presentations and a ECA finalist. Celebrating at last night’s dinner!

@ATandonMD @DebbieKwonMD @CleClinicCIRC @CleClinicHVTI @CleClinicLCM

[Myocarditis Fndn @myocarditisfndn]

The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic!

Read about his work below.

https://t.co/bJRgkUzYCF

[American College of Cardiology @ACCinTouch]

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency?

A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations.

https://t.co/sMG36A0Vtw #JACCHF

[JACC Journals @JACCJournals]

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. https://t.co/oHVc5f7C2i

@CVCTForum @PieterMartensMD @WilsonTangMD